In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers

Expert Rev Vaccines. 2022 Jun;21(6):735-738. doi: 10.1080/14760584.2022.2064279. Epub 2022 Apr 15.

Authors

Matti Lehtinen^{1

2}, Penelope Gray^{1

3}, Karolina Louvanto³, Simopekka Vänskä⁴

Affiliations

¹ Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
² Tampere University Hospital, Tampere, Finland.
³ Tampere University, Tampere, Finland.
⁴ National Institute for Health and Welfare, Helsinki, Finland.

PMID: 35404177
DOI: 10.1080/14760584.2022.2064279

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Alphapapillomavirus*
Early Detection of Cancer
Female
Humans
Neoplasms* / prevention & control
Papillomaviridae
Papillomavirus Infections* / complications
Papillomavirus Infections* / epidemiology
Papillomavirus Infections* / prevention & control
Papillomavirus Vaccines*
Uterine Cervical Neoplasms* / epidemiology
Uterine Cervical Neoplasms* / prevention & control
Vaccination

Substances

Papillomavirus Vaccines